Review





Similar Products

runx2  (Bioss)
95
Bioss runx2
Runx2, supplied by Bioss, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/runx1/RUNX1+%2B+RUNX2+Polyclonal+Antibody/pm42773115-416-11-12
Average 95 stars, based on 1 article reviews
runx2 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology sirnas
Sirnas, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/runx1/RUNX1+siRNA/pm42864323-370-19-23
Average 93 stars, based on 1 article reviews
sirnas - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Proteintech antibody against runx1
Antibody Against Runx1, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/runx1/RUNX1+(middle)+Antibody/pm42828898-86-14-19
Average 94 stars, based on 1 article reviews
antibody against runx1 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

95
Bioss marker genes
Marker Genes, supplied by Bioss, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/runx1/RUNX1+%2B+RUNX2+Polyclonal+Antibody/10__1186_slash_s12864___026___13226___4-77-5-9
Average 95 stars, based on 1 article reviews
marker genes - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

94
ABclonal Biotechnology bca
Bca, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/runx1/RUNX1+Rabbit+pAb/pm42612589-76-14-20
Average 94 stars, based on 1 article reviews
bca - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Santa Cruz Biotechnology mouse monoclonal anti runx1 antibody
Mouse Monoclonal Anti Runx1 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/runx1/RUNX1+Antibody/pm41985437-275-208-213
Average 94 stars, based on 1 article reviews
mouse monoclonal anti runx1 antibody - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Proteintech runx1
A. Scatter plot showing the Z-scored average log2 fold change (LFC) of gene knockout effects in Rh30 cells treated with BI-1347 versus DMSO at day 14 (y-axis) and day 21 (x-axis) from genome-wide CRISPR-Cas9 screens. Each point represents an individual gene; dot size corresponds to statistical significance, and dot color indicates classification. B. Bubble plot of C5 gene sets enriched in GSEA at day 21 in the CRISPR-Cas9 BI-1347 drug modifier screen. C. Box and whisker plots showing construct-level Z-score averages for individual genes in the SAGA complex from the genome-wide CRISPR-Cas9 screen in Rh30 cells treated with DMSO (gray/black) or BI-1347 (blue/red) for 14 days (gray and blue) or 21 days (black and red). Genes are grouped by SAGA functional modules. Boxes indicate the median and interquartile range (IQR; 25 th -75 th percentile); whiskers extend to 1.5x the IQR. Values beyond the end of the whiskers are plotted individually. D. Quantitative real-time TaqMan qPCR analysis of <t>RUNX1</t> , SEMA3D , VGLL 2, and MYL1 expression at day 7 following treatment with vehicle control (DMSO), CDK8 inhibitors, or GSK699, and the indicated combination treatments. Expression levels were normalized to GAPDH gene expression and shown relative to DMSO control. Data represent means ± SEM (n=3; Statistics analysis is showed in Table. S1G ). E-G. Live cell proliferation assessed by Incucyte for BI-1347+/−sgTADA2B ( E ), BI-1347+/−sgTAF5L ( F ), and BI-1347+/−GSK699 ( G ) in Rh30 cells. Data are presented as mean ± SEM (n=3; AUC *** p <=1.0e-03). H. Relative growth was assessed by CellTiter-Glo for Rh28 cells with the treatment of BI-1347+/−sgTADA2B and SEL-120–34A+/−sgTADA2B. Data are presented as mean ± SEM (n=6; AUC ** p <=1.0e-02). I. Line graph reveals mean subcutaneous tumor volume (mm 3 ) formed by Rh28_sgChr2.2 or Rh28_sgTADA2B cells after treatment with the CDK8 inhibitor SEL-120–34A. Data are presented as mean ± SEM (n_sgChr2.2-Vehicle=12, n_sgChr2.2-SEL-120–34A=11, n_sgTADA2B-Vehible=12, n_sgTADA2B-SEL-120–34A-12; AUC *: p <=5.0e-02).
Runx1, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/runx1/RUNX1+(N-terminal)+Antibody/pmc13629752-580-117-118
Average 94 stars, based on 1 article reviews
runx1 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

86
Abbott Laboratories runx1 runx1t1
A. Scatter plot showing the Z-scored average log2 fold change (LFC) of gene knockout effects in Rh30 cells treated with BI-1347 versus DMSO at day 14 (y-axis) and day 21 (x-axis) from genome-wide CRISPR-Cas9 screens. Each point represents an individual gene; dot size corresponds to statistical significance, and dot color indicates classification. B. Bubble plot of C5 gene sets enriched in GSEA at day 21 in the CRISPR-Cas9 BI-1347 drug modifier screen. C. Box and whisker plots showing construct-level Z-score averages for individual genes in the SAGA complex from the genome-wide CRISPR-Cas9 screen in Rh30 cells treated with DMSO (gray/black) or BI-1347 (blue/red) for 14 days (gray and blue) or 21 days (black and red). Genes are grouped by SAGA functional modules. Boxes indicate the median and interquartile range (IQR; 25 th -75 th percentile); whiskers extend to 1.5x the IQR. Values beyond the end of the whiskers are plotted individually. D. Quantitative real-time TaqMan qPCR analysis of <t>RUNX1</t> , SEMA3D , VGLL 2, and MYL1 expression at day 7 following treatment with vehicle control (DMSO), CDK8 inhibitors, or GSK699, and the indicated combination treatments. Expression levels were normalized to GAPDH gene expression and shown relative to DMSO control. Data represent means ± SEM (n=3; Statistics analysis is showed in Table. S1G ). E-G. Live cell proliferation assessed by Incucyte for BI-1347+/−sgTADA2B ( E ), BI-1347+/−sgTAF5L ( F ), and BI-1347+/−GSK699 ( G ) in Rh30 cells. Data are presented as mean ± SEM (n=3; AUC *** p <=1.0e-03). H. Relative growth was assessed by CellTiter-Glo for Rh28 cells with the treatment of BI-1347+/−sgTADA2B and SEL-120–34A+/−sgTADA2B. Data are presented as mean ± SEM (n=6; AUC ** p <=1.0e-02). I. Line graph reveals mean subcutaneous tumor volume (mm 3 ) formed by Rh28_sgChr2.2 or Rh28_sgTADA2B cells after treatment with the CDK8 inhibitor SEL-120–34A. Data are presented as mean ± SEM (n_sgChr2.2-Vehicle=12, n_sgChr2.2-SEL-120–34A=11, n_sgTADA2B-Vehible=12, n_sgTADA2B-SEL-120–34A-12; AUC *: p <=5.0e-02).
Runx1 Runx1t1, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/runx1/dna+her2+kit+pathvysion+probe/pm42283395-36-8-22
Average 86 stars, based on 1 article reviews
runx1 runx1t1 - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Obio Technology Corp Ltd runx1
A. Scatter plot showing the Z-scored average log2 fold change (LFC) of gene knockout effects in Rh30 cells treated with BI-1347 versus DMSO at day 14 (y-axis) and day 21 (x-axis) from genome-wide CRISPR-Cas9 screens. Each point represents an individual gene; dot size corresponds to statistical significance, and dot color indicates classification. B. Bubble plot of C5 gene sets enriched in GSEA at day 21 in the CRISPR-Cas9 BI-1347 drug modifier screen. C. Box and whisker plots showing construct-level Z-score averages for individual genes in the SAGA complex from the genome-wide CRISPR-Cas9 screen in Rh30 cells treated with DMSO (gray/black) or BI-1347 (blue/red) for 14 days (gray and blue) or 21 days (black and red). Genes are grouped by SAGA functional modules. Boxes indicate the median and interquartile range (IQR; 25 th -75 th percentile); whiskers extend to 1.5x the IQR. Values beyond the end of the whiskers are plotted individually. D. Quantitative real-time TaqMan qPCR analysis of <t>RUNX1</t> , SEMA3D , VGLL 2, and MYL1 expression at day 7 following treatment with vehicle control (DMSO), CDK8 inhibitors, or GSK699, and the indicated combination treatments. Expression levels were normalized to GAPDH gene expression and shown relative to DMSO control. Data represent means ± SEM (n=3; Statistics analysis is showed in Table. S1G ). E-G. Live cell proliferation assessed by Incucyte for BI-1347+/−sgTADA2B ( E ), BI-1347+/−sgTAF5L ( F ), and BI-1347+/−GSK699 ( G ) in Rh30 cells. Data are presented as mean ± SEM (n=3; AUC *** p <=1.0e-03). H. Relative growth was assessed by CellTiter-Glo for Rh28 cells with the treatment of BI-1347+/−sgTADA2B and SEL-120–34A+/−sgTADA2B. Data are presented as mean ± SEM (n=6; AUC ** p <=1.0e-02). I. Line graph reveals mean subcutaneous tumor volume (mm 3 ) formed by Rh28_sgChr2.2 or Rh28_sgTADA2B cells after treatment with the CDK8 inhibitor SEL-120–34A. Data are presented as mean ± SEM (n_sgChr2.2-Vehicle=12, n_sgChr2.2-SEL-120–34A=11, n_sgTADA2B-Vehible=12, n_sgTADA2B-SEL-120–34A-12; AUC *: p <=5.0e-02).
Runx1, supplied by Obio Technology Corp Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/runx1/expression+over+plasmid+runx1/pm42250721-76-3-15
Average 86 stars, based on 1 article reviews
runx1 - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Jackson Laboratory runx1
<t>Cdh5-CreERT2;Runx1(flox/flox);SOX17enhKO</t> triple transgenic SRV mice were subjected to mild SuHx treatment. When the SRV mice were treated with corn oil without tamoxifen, they developed significantly elevated RVSP. When the SRV mice were treated with tamoxifen and placed under mild SuHx conditions, they exhibited normal RVSP. **** P < 0.0001.
Runx1, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/runx1/flox+flox+runx1/bio_rxiv__64898__2026__05__14__725187-138-19-21
Average 86 stars, based on 1 article reviews
runx1 - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

Image Search Results


A. Scatter plot showing the Z-scored average log2 fold change (LFC) of gene knockout effects in Rh30 cells treated with BI-1347 versus DMSO at day 14 (y-axis) and day 21 (x-axis) from genome-wide CRISPR-Cas9 screens. Each point represents an individual gene; dot size corresponds to statistical significance, and dot color indicates classification. B. Bubble plot of C5 gene sets enriched in GSEA at day 21 in the CRISPR-Cas9 BI-1347 drug modifier screen. C. Box and whisker plots showing construct-level Z-score averages for individual genes in the SAGA complex from the genome-wide CRISPR-Cas9 screen in Rh30 cells treated with DMSO (gray/black) or BI-1347 (blue/red) for 14 days (gray and blue) or 21 days (black and red). Genes are grouped by SAGA functional modules. Boxes indicate the median and interquartile range (IQR; 25 th -75 th percentile); whiskers extend to 1.5x the IQR. Values beyond the end of the whiskers are plotted individually. D. Quantitative real-time TaqMan qPCR analysis of RUNX1 , SEMA3D , VGLL 2, and MYL1 expression at day 7 following treatment with vehicle control (DMSO), CDK8 inhibitors, or GSK699, and the indicated combination treatments. Expression levels were normalized to GAPDH gene expression and shown relative to DMSO control. Data represent means ± SEM (n=3; Statistics analysis is showed in Table. S1G ). E-G. Live cell proliferation assessed by Incucyte for BI-1347+/−sgTADA2B ( E ), BI-1347+/−sgTAF5L ( F ), and BI-1347+/−GSK699 ( G ) in Rh30 cells. Data are presented as mean ± SEM (n=3; AUC *** p <=1.0e-03). H. Relative growth was assessed by CellTiter-Glo for Rh28 cells with the treatment of BI-1347+/−sgTADA2B and SEL-120–34A+/−sgTADA2B. Data are presented as mean ± SEM (n=6; AUC ** p <=1.0e-02). I. Line graph reveals mean subcutaneous tumor volume (mm 3 ) formed by Rh28_sgChr2.2 or Rh28_sgTADA2B cells after treatment with the CDK8 inhibitor SEL-120–34A. Data are presented as mean ± SEM (n_sgChr2.2-Vehicle=12, n_sgChr2.2-SEL-120–34A=11, n_sgTADA2B-Vehible=12, n_sgTADA2B-SEL-120–34A-12; AUC *: p <=5.0e-02).

Journal: Cancer discovery

Article Title: CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma

doi: 10.1158/2159-8290.CD-25-1171

Figure Lengend Snippet: A. Scatter plot showing the Z-scored average log2 fold change (LFC) of gene knockout effects in Rh30 cells treated with BI-1347 versus DMSO at day 14 (y-axis) and day 21 (x-axis) from genome-wide CRISPR-Cas9 screens. Each point represents an individual gene; dot size corresponds to statistical significance, and dot color indicates classification. B. Bubble plot of C5 gene sets enriched in GSEA at day 21 in the CRISPR-Cas9 BI-1347 drug modifier screen. C. Box and whisker plots showing construct-level Z-score averages for individual genes in the SAGA complex from the genome-wide CRISPR-Cas9 screen in Rh30 cells treated with DMSO (gray/black) or BI-1347 (blue/red) for 14 days (gray and blue) or 21 days (black and red). Genes are grouped by SAGA functional modules. Boxes indicate the median and interquartile range (IQR; 25 th -75 th percentile); whiskers extend to 1.5x the IQR. Values beyond the end of the whiskers are plotted individually. D. Quantitative real-time TaqMan qPCR analysis of RUNX1 , SEMA3D , VGLL 2, and MYL1 expression at day 7 following treatment with vehicle control (DMSO), CDK8 inhibitors, or GSK699, and the indicated combination treatments. Expression levels were normalized to GAPDH gene expression and shown relative to DMSO control. Data represent means ± SEM (n=3; Statistics analysis is showed in Table. S1G ). E-G. Live cell proliferation assessed by Incucyte for BI-1347+/−sgTADA2B ( E ), BI-1347+/−sgTAF5L ( F ), and BI-1347+/−GSK699 ( G ) in Rh30 cells. Data are presented as mean ± SEM (n=3; AUC *** p <=1.0e-03). H. Relative growth was assessed by CellTiter-Glo for Rh28 cells with the treatment of BI-1347+/−sgTADA2B and SEL-120–34A+/−sgTADA2B. Data are presented as mean ± SEM (n=6; AUC ** p <=1.0e-02). I. Line graph reveals mean subcutaneous tumor volume (mm 3 ) formed by Rh28_sgChr2.2 or Rh28_sgTADA2B cells after treatment with the CDK8 inhibitor SEL-120–34A. Data are presented as mean ± SEM (n_sgChr2.2-Vehicle=12, n_sgChr2.2-SEL-120–34A=11, n_sgTADA2B-Vehible=12, n_sgTADA2B-SEL-120–34A-12; AUC *: p <=5.0e-02).

Article Snippet: Primary antibodies used in this study includes: CDK8 (ProteinTech, #22067; Cell Signaling Technology, #4106S; Santa Cruz Biotechnology, #SC-13155; Abcam, #ab229192), STAT1 (Cell Signaling Technology, #9176S), pSTAT1S727 (Cell Signaling Technology, #8826S), SIX4 (Santa Cruz Biotechnology, #SC-390779), GAPDH (Santa Cruz Biotechnology, #SC-365062), LaminB (Abcam, #ab16048; Santa Cruz Biotechnology, #SC-374015), ACTB (Sigma Aldrich, #A2066), total PARP (Cell Signaling Technology, #9542S), cleaved PARP (Cell Signaling Technology, #5625S), cleaved caspase 3 (Cell Signaling Technology, #9664S), FOXO1 (Cell Signaling Technology, #2380S), PAX3::FOXO1 (CancerTools, #160866), MYC (EMD Milipore, #05–724), Streptavidin-HRP (Cell Signaling Technology, #3999), TAF5L (ProteinTech, #19274), TADA2B (ProteinTech, #17367), KAT2A (ProteinTech, #66575), KAT2B (Cell Signaling Technology, #C14G9), CCNC (ProteinTech, #26464), MED13 (ProteinTech, #26464), MED12 (ProteinTech, #20028), MED1 (Bethyl Laboratories, #A300–793A), MEF2C (Abcam, #ab221493), RUNX1 (ProteinTech, #25315), MYL1 (ProteinTech, #15814), MF20 (Fisher Scientific, #MAB4470), FLAG (Sigma, #F3165).

Techniques: Gene Knockout, Genome Wide, CRISPR, Whisker Assay, Construct, Functional Assay, Analysis, Expressing, Control, Gene Expression

A. Box and whisker plots showing construct-level Z-score averages for individual genes in the Mediator complex from a genome-wide CRISPR-Cas9 screen in Rh30 cells treated with DMSO (gray/black) or BI-1347 (blue/red) for 14 days (gray and blue) or 21 days (black and red). Genes are grouped by Mediator functional modules. Boxes indicate the median and interquartile range (IQR; 25 th -75 th percentile); whiskers extend to 1.5x the IQR. Values beyond the end of the whiskers are plotted individually. B. Live cell proliferation assessed by Incucyte for BI-1347+/−sgCCNC (blue) or sgCDK8 (red). Data represent means ± SEM (n=3; AUC **: p <=1.0e-02, ***: p <= 1.0e-03) C. MA plot showing changes of CDK8 binding site assessed by CUT&RUN after 24 hrs of BI-1347 treatment. Significantly increased CDK8 peaks are highlighted in red; significantly decreased CDK8 peaks are highlighted in blue (padj<0.05, fold change>1.5 or <−1.5). D. Motif analysis of the regions with increased CDK8 DNA binding peaks from CUT&RUN analysis in Rh30 cells. E. Heatmaps showing chromatin occupancy of CDK8, CCNC, MED12, MED13, and MED1 at regions with upregulated SIX4 binding at 24 hrs of DMSO or BI-1347 treatment. F. IGV gene tracks showing the PRO-seq, CDK8, CCNC, MED12, and MED1 binding at the RUNX1 gene body and enhancer loci at indicated time points after BI-1347 treatment.

Journal: Cancer discovery

Article Title: CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma

doi: 10.1158/2159-8290.CD-25-1171

Figure Lengend Snippet: A. Box and whisker plots showing construct-level Z-score averages for individual genes in the Mediator complex from a genome-wide CRISPR-Cas9 screen in Rh30 cells treated with DMSO (gray/black) or BI-1347 (blue/red) for 14 days (gray and blue) or 21 days (black and red). Genes are grouped by Mediator functional modules. Boxes indicate the median and interquartile range (IQR; 25 th -75 th percentile); whiskers extend to 1.5x the IQR. Values beyond the end of the whiskers are plotted individually. B. Live cell proliferation assessed by Incucyte for BI-1347+/−sgCCNC (blue) or sgCDK8 (red). Data represent means ± SEM (n=3; AUC **: p <=1.0e-02, ***: p <= 1.0e-03) C. MA plot showing changes of CDK8 binding site assessed by CUT&RUN after 24 hrs of BI-1347 treatment. Significantly increased CDK8 peaks are highlighted in red; significantly decreased CDK8 peaks are highlighted in blue (padj<0.05, fold change>1.5 or <−1.5). D. Motif analysis of the regions with increased CDK8 DNA binding peaks from CUT&RUN analysis in Rh30 cells. E. Heatmaps showing chromatin occupancy of CDK8, CCNC, MED12, MED13, and MED1 at regions with upregulated SIX4 binding at 24 hrs of DMSO or BI-1347 treatment. F. IGV gene tracks showing the PRO-seq, CDK8, CCNC, MED12, and MED1 binding at the RUNX1 gene body and enhancer loci at indicated time points after BI-1347 treatment.

Article Snippet: Primary antibodies used in this study includes: CDK8 (ProteinTech, #22067; Cell Signaling Technology, #4106S; Santa Cruz Biotechnology, #SC-13155; Abcam, #ab229192), STAT1 (Cell Signaling Technology, #9176S), pSTAT1S727 (Cell Signaling Technology, #8826S), SIX4 (Santa Cruz Biotechnology, #SC-390779), GAPDH (Santa Cruz Biotechnology, #SC-365062), LaminB (Abcam, #ab16048; Santa Cruz Biotechnology, #SC-374015), ACTB (Sigma Aldrich, #A2066), total PARP (Cell Signaling Technology, #9542S), cleaved PARP (Cell Signaling Technology, #5625S), cleaved caspase 3 (Cell Signaling Technology, #9664S), FOXO1 (Cell Signaling Technology, #2380S), PAX3::FOXO1 (CancerTools, #160866), MYC (EMD Milipore, #05–724), Streptavidin-HRP (Cell Signaling Technology, #3999), TAF5L (ProteinTech, #19274), TADA2B (ProteinTech, #17367), KAT2A (ProteinTech, #66575), KAT2B (Cell Signaling Technology, #C14G9), CCNC (ProteinTech, #26464), MED13 (ProteinTech, #26464), MED12 (ProteinTech, #20028), MED1 (Bethyl Laboratories, #A300–793A), MEF2C (Abcam, #ab221493), RUNX1 (ProteinTech, #25315), MYL1 (ProteinTech, #15814), MF20 (Fisher Scientific, #MAB4470), FLAG (Sigma, #F3165).

Techniques: Activity Assay, Whisker Assay, Construct, Genome Wide, CRISPR, Functional Assay, Binding Assay, Analysis

Cdh5-CreERT2;Runx1(flox/flox);SOX17enhKO triple transgenic SRV mice were subjected to mild SuHx treatment. When the SRV mice were treated with corn oil without tamoxifen, they developed significantly elevated RVSP. When the SRV mice were treated with tamoxifen and placed under mild SuHx conditions, they exhibited normal RVSP. **** P < 0.0001.

Journal: bioRxiv

Article Title: Impaired SOX17 Expression Causes Endothelial Dysfunction and Pulmonary Arterial Hypertension by Insufficient Suppression of RUNX1

doi: 10.64898/2026.05.14.725187

Figure Lengend Snippet: Cdh5-CreERT2;Runx1(flox/flox);SOX17enhKO triple transgenic SRV mice were subjected to mild SuHx treatment. When the SRV mice were treated with corn oil without tamoxifen, they developed significantly elevated RVSP. When the SRV mice were treated with tamoxifen and placed under mild SuHx conditions, they exhibited normal RVSP. **** P < 0.0001.

Article Snippet: In order to inducibly delete RUNX1 in adult endothelium, we crossbred Cdh5(PAC)-CreERT2 mice (Taconic Cat# 13073, Rensselaer, NY) with Runx1(flox/flox) mice (Jackson Laboratory Cat# 008772, Bar Harbor, ME) and generated Cdh5-CreERT2;Runx1(flox/flox) mice in our lab . Mice with correct genotype were each treated with 2 mg of tamoxifen daily via intraperitoneal injection for 5 days followed by 1 week of incubation.

Techniques: Transgenic Assay